A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.

IF 0.2 4区生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Law Report Pub Date : 2022-03-03 DOI:10.1089/blr.2022.29262.phc

Ping-hsun Chen

引用次数: 0

查看原文本刊更多论文

根据35 U.S.C.§112:Horizon Pharma, Inc.诉Dr. Reddy's Laboratories Inc.的教训，作为权利要求条款的药物制剂不能“瞄准”血浆浓度-时间剖面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Law Report 工程技术-生物工程与应用微生物

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The leading authoritative journal since 1982 devoted to the evolving body of law and government regulation concerning biotechnology, particularly in the industries in which new products from these technologies are developing the most rapidly: pharmaceuticals, chemicals, agriculture, food processing, energy, mineral recovery, and waste treatment. All legal aspects are rapidly reported, and critical and often hard-to-obtain documents are reproduced.